Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· July 23, 2026
Novocure Reports Second Quarter 2026 Financial Results
View original at finance.yahoo.comNovocure Reports Second Quarter 2026 Financial Results Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU M…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
This was Novocure's strongest quarter to date, with record net revenues and active patients on therapy; the company continues to launch its therapies in multiple markets and is making material progress on its path to profitability.
60% confidence
Cited in these Via News reports
- AI-Designed Biologics and Personalized mRNA Vaccines: What the Oncology Evidence Supports, and What It Doesn't →
- AstraZeneca Says Its Data Will Train Better Cancer Drugs. Its Pitch Rests on a Source That Failed Our Check. →
- AstraZeneca's 'Lab of the Future' Pitch Meets the Hard Part: Safety Prediction, and a Bispecific Biotech Burning Cash →
- AstraZeneca's AI 'Lab of the Future' Meets a Crowded Oncology Pipeline: What Is Proven, and What Is Still a Promise →
- AstraZeneca's AI Drug-Design Vision Is Still a Forecast, While Oncology's Near-Term Catalysts Are Conventional →
- AstraZeneca's AI-Designed-Biologics Pitch Is a Forecast, Not a Result: What the Oncology Pipeline Actually Shows →
- AstraZeneca's AI-to-Lab Loop Meets a Crowded Oncology Calendar, and the Evidence for It Is Still Thin →
- Before ESMO 2026, AI's role in cancer drug discovery rests on promises, not yet on measured results →
- Oncology's Q4 Catalyst Season Meets Pharma's AI Pitch: What Is Verified, and What Is Still a Claim →
